In:
International Journal of Cancer, Wiley, Vol. 137, No. 12 ( 2015-12-15), p. 2971-2980
Abstract:
What's new? The implementation of the pharmacogenetics in clinical practice is still sporadic despite the recent publication of specific guidelines. Our study demonstrates, in a large group of cancer cases from the current clinical practice, that among a panel of eight DPYD genetic polymorphisms, the three‐markers test ( DPYD ‐rs3918290, DPYD ‐rs55886062, DPYD ‐rs67376798) is the most specific to predict fluoropyrimidines‐related severe and chronic toxicities encouraging the implementation of this pharmacogenetic test as part of the everyday practice in oncology.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Bookmarklink